GeneDx has completed the acquisition of Fabric Genomics, a US-based company focused on AI-driven human genomic interpretation. The two companies now aim to focus on the next generation of genomic medicine, facilitating decentralised testing with centralised intelligence. Last month, GeneDx announced its plans to acquire Fabric Genomics, with an aggregate payment of up to $33m in cash at closure. The deal value could potentially go up to an aggregate of $51m after achieving specific milestones. The exome and genome testing and rare disease data assets of GeneDx, combined with the AI interpretation services of Fabric Genomics will create a genomic diagnostic ecosystem. GeneDx noted that the integrated model provides flexibility for healthcare providers and systems, offering a seamless workflow for centralised and decentralised genomic services. This synergy is powered by GeneDx's clinical expertise and interpretation technology of Fabric. Fabric Genomics will maintain its operational independence as GeneDx’s subsidiary, advancing its growth trajectory with commercial backing from its new parent company. The acquisition unlocks several growth avenues for GeneDx, including expediting neonatal intensive care unit (NICU) genomic testing to swiftly diagnose critically ill newborns, positioning the company to support large-scale genomic newborn screening (gNBS) programmes worldwide. Additionally, the acquisition will allow for models that are regulation-compliant for AI-powered interpretation services throughout various global regions. It also taps into recurring revenue streams that are based on software via Fabric Genomics’ interpretation-as-a-service model. Fenwick & West acted as the legal adviser for GeneDx during this acquisition. Meanwhile, TD Cowen provided exclusive financial advice to Fabric Genomics, with DLA Piper (US) offering legal counsel. GeneDx CEO and president Katherine Stueland said: “Healthcare is at an inflexion point where genomic insights must be integrated into standard care to improve outcomes and reduce costs. “With Fabric Genomics now part of GeneDx, we’re uniquely positioned to deliver earlier and more accurate diagnoses worldwide, from NICUs and pioneering newborn screening programmes to health systems across the globe.” "GeneDx completes acquisition of Fabric Genomics" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments
GeneDx completes acquisition of Fabric Genomics
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...